Gideon Lack | Evelina Childrens Hospital | London, UK
Evelina Children's Hospital | London, United Kingdom
ITN070AD
Active
LEAP Trio is a follow-up assessment of the LEAP randomized controlled study of early peanut consumption during which we found that in high-risk infants, sustained consumption of peanut beginning in the first 11 months of life was highly effective in preventing the development of peanut allergy. The primary objectives of LEAP Trio are threefold:
LEAP participants are followed during an extended period of ad-libitum peanut consumption and then assessed for peanut allergy and other allergic outcomes at age 12. In addition, siblings will be randomly assigned to the intervention or control group based on the allocation of their LEAP participant siblings.